Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GYS1 | P13807 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288651 | 1.00 | P2RX7 (0.56) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL288652 | 1.00 | P2RX7 (0.56) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL1612123 | 0.91 | CAPN1 (0.63) | P2RX7CAPN1HCRTR1HCRTR2 | |
| SCHEMBL288455 | 0.91 | CAPN1 (0.63) | P2RX7CAPN1HCRTR1HCRTR2 | |
| SCHEMBL1162700 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL1162612 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL28270409 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL5741011 | 0.90 | KMT2A (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL19975206 | 0.88 | P2RX7 (0.54) | P2RX7KMT2AGAAALDH1A1HCRTR1 | |
| SCHEMBL19975137 | 0.88 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-6348477-B1 | SUBSTITUTED PHENYL THIAZOLE DERIVATIVES AS VIRICIDES | BOEHRINGER INGELHEIM(CANADA) LTD. (CA) | 2002-02-19 | — | — | US | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6288091-B1 | COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX | BOEHRINGER INGELHEIM LTD. (CA) | 2001-09-11 | — | — | US | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6057451-A | AMINOTHIAZOLE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | P2RX7 2958/4885CAPN1 3/4885KMT2A 4418/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | P2RX7 564/4885CAPN1 1555/4885KMT2A 4177/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | P2RX7 2213/4885CAPN1 4/4885KMT2A 4469/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | P2RX7 2406/4885CAPN1 191/4885KMT2A 1833/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | P2RX7 2958/4885CAPN1 3/4885KMT2A 4418/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | P2RX7 712/4885CAPN1 86/4885KMT2A 2410/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | P2RX7 339/4885CAPN1 1497/4885KMT2A 4031/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.